EP2698375A3 - Modulateurs de TGR5 et leur procédé d'utilisation - Google Patents

Modulateurs de TGR5 et leur procédé d'utilisation Download PDF

Info

Publication number
EP2698375A3
EP2698375A3 EP13192394.8A EP13192394A EP2698375A3 EP 2698375 A3 EP2698375 A3 EP 2698375A3 EP 13192394 A EP13192394 A EP 13192394A EP 2698375 A3 EP2698375 A3 EP 2698375A3
Authority
EP
European Patent Office
Prior art keywords
disease
compounds
tgr5 modulators
formula
tgr5
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP13192394.8A
Other languages
German (de)
English (en)
Other versions
EP2698375A2 (fr
EP2698375B1 (fr
Inventor
Roberto Pellicciari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intercept Pharmaceuticals Inc
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41668454&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2698375(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Priority to SI200931820T priority Critical patent/SI2698375T1/sl
Priority to NO13192394A priority patent/NO2698375T3/no
Priority to EP13192394.8A priority patent/EP2698375B1/fr
Priority to PL13192394T priority patent/PL2698375T3/pl
Publication of EP2698375A2 publication Critical patent/EP2698375A2/fr
Publication of EP2698375A3 publication Critical patent/EP2698375A3/fr
Application granted granted Critical
Publication of EP2698375B1 publication Critical patent/EP2698375B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP13192394.8A 2008-11-19 2009-11-19 Modulateurs de TGR5 et leur procédé d'utilisation Active EP2698375B1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
SI200931820T SI2698375T1 (sl) 2008-11-19 2009-11-19 Modulatorji TGR5 in njihova uporaba
NO13192394A NO2698375T3 (fr) 2008-11-19 2009-11-19
EP13192394.8A EP2698375B1 (fr) 2008-11-19 2009-11-19 Modulateurs de TGR5 et leur procédé d'utilisation
PL13192394T PL2698375T3 (pl) 2008-11-19 2009-11-19 Modulatory TGR5 i sposób ich zastosowania

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08169462 2008-11-19
EP09760057.1A EP2376519B1 (fr) 2008-11-19 2009-11-19 Modulateurs de tgr5 et leur procédé d'utilisation
EP13192394.8A EP2698375B1 (fr) 2008-11-19 2009-11-19 Modulateurs de TGR5 et leur procédé d'utilisation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP09760057.1A Division EP2376519B1 (fr) 2008-11-19 2009-11-19 Modulateurs de tgr5 et leur procédé d'utilisation

Publications (3)

Publication Number Publication Date
EP2698375A2 EP2698375A2 (fr) 2014-02-19
EP2698375A3 true EP2698375A3 (fr) 2014-03-12
EP2698375B1 EP2698375B1 (fr) 2018-02-21

Family

ID=41668454

Family Applications (2)

Application Number Title Priority Date Filing Date
EP09760057.1A Active EP2376519B1 (fr) 2008-11-19 2009-11-19 Modulateurs de tgr5 et leur procédé d'utilisation
EP13192394.8A Active EP2698375B1 (fr) 2008-11-19 2009-11-19 Modulateurs de TGR5 et leur procédé d'utilisation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP09760057.1A Active EP2376519B1 (fr) 2008-11-19 2009-11-19 Modulateurs de tgr5 et leur procédé d'utilisation

Country Status (23)

Country Link
US (5) US8114862B2 (fr)
EP (2) EP2376519B1 (fr)
JP (5) JP5535233B2 (fr)
KR (2) KR101789960B1 (fr)
CN (2) CN104370990A (fr)
AU (1) AU2009316566B9 (fr)
BR (1) BRPI0921983B8 (fr)
CA (1) CA2744189C (fr)
DK (2) DK2376519T3 (fr)
EA (2) EA030681B1 (fr)
ES (2) ES2458168T3 (fr)
HK (2) HK1166327A1 (fr)
HU (1) HUE039171T2 (fr)
IL (3) IL212969A (fr)
LT (1) LT2698375T (fr)
MX (1) MX2011005295A (fr)
NO (1) NO2698375T3 (fr)
PL (2) PL2376519T3 (fr)
PT (2) PT2376519E (fr)
SG (1) SG10201400162QA (fr)
SI (1) SI2698375T1 (fr)
WO (1) WO2010059853A1 (fr)
ZA (1) ZA201104077B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE303399T1 (de) 2001-03-12 2005-09-15 Intercept Pharmaceuticals Inc Steroide als agonisten für fxr
ES2533993T3 (es) 2004-03-12 2015-04-16 Intercept Pharmaceuticals, Inc. Tratamiento de fibrosis usando ligandos de FXR
US10987362B2 (en) 2004-03-12 2021-04-27 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using FXR ligands
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
EP2112995B1 (fr) 2007-01-19 2013-07-31 Intercept Pharmaceuticals, Inc. Acides biliares substitues en 23 utiles comme modulateurs de tgr5 et leurs methodes d'utilisation
CN102164940B (zh) 2008-07-30 2015-08-19 英特塞普特医药品公司 Tgr5调节剂及其使用方法
PT2376519E (pt) * 2008-11-19 2014-02-20 Intercept Pharmaceuticals Inc Moduladores de tgr5 e métodos da sua utilização
CN102316872B (zh) 2008-11-26 2016-12-21 萨蒂奥根制药公司 治疗肥胖症和糖尿病的胆汁酸再循环抑制剂
EP2364161B1 (fr) 2008-11-26 2020-03-11 Satiogen Pharmaceuticals, Inc. Compositions contenant des satiogènes et leurs procédés d'utilisation
ES2552657T3 (es) 2010-05-26 2015-12-01 Satiogen Pharmaceuticals, Inc. Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
SG10201407013QA (en) 2011-10-28 2014-12-30 Lumena Pharmaceuticals Inc Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
US9982008B2 (en) 2012-06-19 2018-05-29 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
US9238673B2 (en) 2012-06-19 2016-01-19 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
EP2906197A1 (fr) 2012-10-09 2015-08-19 The Procter & Gamble Company Procédé d'identification de combinaisons cosmétiques synergiques
EP2906946A1 (fr) 2012-10-09 2015-08-19 The Procter & Gamble Company Procédé d'identification ou d'évaluation de principes actifs bénéfiques, et compositions contenant ces derniers
EP3004132A4 (fr) * 2013-06-06 2017-01-18 Yissum, Research Development Company of the Hebrew Conjugués acides biliaires-acides aminés basiques et leurs utilisations
US20160151486A1 (en) * 2013-06-13 2016-06-02 Fast Foward Pharmaceuticals B.V. CD40 Signalling Inhibitor and a Further Compound, Wherein the Further Compound is a Bile Acid, a Bile Acid Derivative, an TGR5-Receptor Agonist, an FXR Agonist or a Combination Thereof, for the Treatment of Chronic Inflammation, and the Prevention of Gastrointestinal Cancer or Fibrosis
JP6621409B2 (ja) 2013-11-22 2019-12-18 ミナ セラピューティクス リミテッド Ｃ／ＥＢＰα小分子活性化ＲＮＡ組成物
PL3626725T3 (pl) 2014-05-29 2023-04-03 Bar Pharmaceuticals S.R.L. Pochodne cholanu do zastosowania w leczeniu i/lub zapobieganiu chorobom, w których pośredniczy fxr i tgr5/gpbar1
US20180236064A1 (en) * 2014-10-03 2018-08-23 Mayo Foundation For Medical Education And Research Targeting tgr5 to treat disease
WO2016073767A1 (fr) * 2014-11-06 2016-05-12 Enanta Pharmaceuticals, Inc. Analogues d'acide biliaire d'agonistes de fxr/tgr5 et leurs procédés d'utilisation
CA2968309A1 (fr) 2014-11-19 2016-05-26 NZP UK Limited Steroides 6-alkyl-7-hydroxy-4-en-3-one utilises en tant qu'intermediaires pour la production de modulateurs de fxr steroidiens
TWI686400B (zh) 2014-11-19 2020-03-01 英商Ｎｚｐ英國有限公司 化合物（二）
EA034739B1 (ru) 2014-11-19 2020-03-16 ЭнЗедПи ЮКей ЛИМИТЕД 6-альфа-алкил-3,7-дионовые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
CN107207558B (zh) 2014-11-19 2019-10-29 Nzp英国有限公司 作为制备类固醇FXR调节剂的中间体的6α-烷基-6,7-二酮类固醇
CN105985396A (zh) * 2015-02-16 2016-10-05 苏州泽璟生物制药有限公司 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
JP2018519246A (ja) * 2015-04-28 2018-07-19 ジエンス ハンセン ファーマセウティカル グループ カンパニー リミテッド コール酸誘導体、及びその製造方法及び医薬用途
DK3310801T3 (da) 2015-06-19 2021-06-21 Intercept Pharmaceuticals Inc Tgr5-modulatorer og fremgangsmåder til anvendelse deraf
WO2016205475A2 (fr) * 2015-06-19 2016-12-22 Intercept Pharmaceuticals, Inc. Modulateurs de tgr5 et leurs procédés d'utilisation
US11072631B2 (en) * 2015-09-24 2021-07-27 Intercept Pharmaceuticals, Inc. Methods and intermediates for the preparation bile acid derivatives
CR20180201A (es) * 2015-10-07 2018-08-24 Intercept Pharmaceuticals Inc Modularores del receptor x farnesoide
CN106008639B (zh) * 2016-03-11 2019-01-08 深圳市塔吉瑞生物医药有限公司 用于预防或治疗fxr-介导疾病的胆烷酸化合物
JP6968821B2 (ja) 2016-04-13 2021-11-17 インターセプト ファーマシューティカルズ， インコーポレイテッド 癌を治療する方法
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
US10654834B2 (en) * 2016-07-01 2020-05-19 Venenum Biodesign, LLC Non-systemic TGR5 agonists
WO2018222701A1 (fr) * 2017-05-30 2018-12-06 Intercept Pharmaceuticals, Inc. Traitement de maladies rénales avec un dérivé d'acide biliaire
CN109021056B (zh) * 2017-06-09 2021-03-09 博瑞生物医药（苏州）股份有限公司 法尼酯x受体激动剂
WO2019023103A1 (fr) 2017-07-24 2019-01-31 Intercept Pharmaceuticals, Inc. Dérivés d'acide biliaire à marquage isotopique
EP4233880A3 (fr) 2017-09-08 2023-09-20 MiNA Therapeutics Limited Compositions de petits arn activateurs de hnf4a et procédés d'utilisation
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
US20220096495A1 (en) * 2019-02-04 2022-03-31 Intercept Pharmaceuticals, Inc. Treatment and prevention of intestinal inflammatory diseases with a bile acid derivative
CN116925168A (zh) * 2019-08-23 2023-10-24 深圳云合医药科技合伙企业(有限合伙) 胆汁酸衍生物及其组合物和应用
KR20220150270A (ko) 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제
CA3178994A1 (fr) 2020-05-19 2021-11-25 Iyassu Sebhat Activateurs d'ampk
JP2023531726A (ja) 2020-06-26 2023-07-25 キャリーオペ，インク． Ａｍｐｋアクチベーター
KR20220004451A (ko) * 2020-07-03 2022-01-11 연세대학교 산학협력단 지방간 질환의 예방 또는 치료를 위한 약학적 조성물
CN113774142A (zh) * 2021-10-11 2021-12-10 北京化工大学 Tgr5在制备治疗肠癌药物及诊断性试剂盒中的应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0101554B1 (fr) 1982-07-29 1986-10-15 Lehner A.G. Dérivés d'acides biliaires, leur procédé de préparation et compositions pharmaceutiques les contenant
IT1206112B (it) 1983-04-29 1989-04-14 Lehner Ag Nuovi derivati di acidi biliari, procedimento per la loro preparazione e relative composizioni farmaceutiche.
IT1212835B (it) 1983-08-18 1989-11-30 Lehner Ag Derivati di acidi biliari, procedimento per la loro preparazione e relative composizioni farmaceutiche.
US4892868A (en) * 1984-08-17 1990-01-09 Gipharmex, S.P.A. Derivatives of biliary acids, process for the production thereof and corresponding pharmaceutical compositions
IT1196377B (it) * 1984-12-21 1988-11-16 Lehner Ag Derivati di acidi biliari,procedimento per la loro preparazione e relative composizioni farmaceutiche
IT1223313B (it) * 1987-10-20 1990-09-19 Gipharmex Spa Derivati di acidi biliari loro preparazione e composizioni farmaceutiche che li contengono
US5175320A (en) * 1989-04-17 1992-12-29 Giuliani S.P.A. Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
IT1229570B (it) * 1989-04-17 1991-09-04 Giuliani Spa Derivati fluorurati di acidi biliari, loro preparazione e composizioni farmaceutiche che li contengono.
DE69018592T2 (de) * 1989-12-13 1995-10-05 Mitsubishi Chem Corp Pyrazolylacrylsäure-Derivate, verwendbar als systemische Fungiziden in Pflanzen- und Materialschutz.
WO1997028149A1 (fr) 1996-02-02 1997-08-07 Merck & Co., Inc. Procede pour augmenter les niveaux de cholesterol hdl
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
US5689791A (en) 1996-07-01 1997-11-18 Xerox Corporation Electrically conductive fibers
BR9710272A (pt) 1996-07-12 1999-08-10 Smithkline Beecham Plc Novo tratamento de resisténcia a leptina
US6008237A (en) * 1997-12-19 1999-12-28 Merck & Co., Inc. Arylthiazolidinedione derivatives
WO1999038845A1 (fr) 1998-01-29 1999-08-05 Tularik Inc. MODULATEURS DU RECEPTEUR ACTIVE DE LA PROLIFERATION DES PEROXYSOMES (PPARη)
JP2002528721A (ja) 1998-10-23 2002-09-03 グラクソ グループ リミテッド 核内受容体のリガンド用のアッセイ
AU2389100A (en) * 1998-12-23 2000-07-12 Glaxo Group Limited Assays for ligands for nuclear receptors
US6465258B1 (en) 1999-01-07 2002-10-15 Tularik, Inc. FXR receptor-mediated modulation cholesterol metabolism
ATE330632T1 (de) 1999-03-26 2006-07-15 Hope City Selektion von fxr-rezeptormodulatoren
US20020132223A1 (en) 1999-03-26 2002-09-19 City Of Hope Methods for modulating activity of the FXR nuclear receptor
EP1473042B1 (fr) 1999-03-26 2006-06-21 City of Hope Criblage de composés modulant l'activité des récepteurs FXR
BR0011743A (pt) 1999-06-11 2002-03-05 Allergan Sales Inc Método para modular a atividade de receptor de fxr
US6906057B1 (en) * 1999-06-11 2005-06-14 Allergan, Inc. Methods for modulating FXR receptor activity
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
EP1284728A4 (fr) 1999-10-22 2004-05-19 Merck & Co Inc Medicaments destines au traitement de l'obesite
EP1273659A4 (fr) 2000-04-12 2004-04-21 Takeda Chemical Industries Ltd Nouvelle proteine de recepteur couple aux proteines g et adn de celle-ci
US6627636B2 (en) * 2000-06-15 2003-09-30 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
WO2002020463A2 (fr) 2000-09-05 2002-03-14 Tularik Inc. Modulateurs fxr
US20020119958A1 (en) 2001-02-13 2002-08-29 Shinichiro Tojo Therapeutic agent for hyperlipidemia
ATE303399T1 (de) * 2001-03-12 2005-09-15 Intercept Pharmaceuticals Inc Steroide als agonisten für fxr
EP1378749A4 (fr) 2001-04-12 2005-05-11 Takeda Pharmaceutical Procede de criblage
EP1423113A4 (fr) 2001-08-13 2007-04-18 Phenex Pharmaceuticals Ag Composes de liaison au recepteur nucleaire nr1h4
WO2003016280A1 (fr) 2001-08-13 2003-02-27 Lion Bioscience Ag Composes liant le recepteur nucleaire nr1h4
EP1285914B1 (fr) 2001-08-13 2007-12-19 PheneX Pharmaceuticals AG Ligands du récepteur nucéaire nr1h4
US20030144360A1 (en) 2001-11-19 2003-07-31 Allergan Sales, Inc. Composition and method for modulating BAR/FXR receptor activity
WO2003080803A2 (fr) 2002-03-21 2003-10-02 Smithkline Beecham Corporation Procedes d'utilisation d'agonistes du recepteur farnesoide x (fxr)
WO2003086303A2 (fr) 2002-04-12 2003-10-23 The University Of Chicago Agonistes de recepteur active frx (farnesoid x receptor)
US6987121B2 (en) * 2002-04-25 2006-01-17 Smithkline Beecham Corporation Compositions and methods for hepatoprotection and treatment of cholestasis
WO2004000752A1 (fr) 2002-06-19 2003-12-31 Availvs Corporation Materiau de paroi en pierre artificielle
ITMI20021532A1 (it) 2002-07-12 2004-01-12 Roberto Pellicciari Composti chimici
WO2004048349A1 (fr) 2002-11-22 2004-06-10 Smithkline Beecham Corporation Agonistes de recepteur farnesoide x
WO2004067008A1 (fr) 2003-01-28 2004-08-12 Takeda Pharmaceutical Company Limited Agonistes de recepteurs
WO2005032549A1 (fr) 2003-09-26 2005-04-14 Smithkline Beecham Corporation Compositions et procedes pour traiter une fibrose
EP1568706A1 (fr) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Nouveau agonist steroidal pour FXR
ES2533993T3 (es) 2004-03-12 2015-04-16 Intercept Pharmaceuticals, Inc. Tratamiento de fibrosis usando ligandos de FXR
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
EP2040713B1 (fr) 2006-06-27 2014-06-18 Intercept Pharmaceuticals Inc. Dérivés de l'acide biliaire en tant que des ligands de fxr pour la prévention ou le traitement de maladies ou conditions médiées par le fxr
EP1947108A1 (fr) 2007-01-19 2008-07-23 Intercept Pharmaceuticals, Inc. Modulateurs TGR5 et procédés d'utilisation correspondants
EP2112995B1 (fr) * 2007-01-19 2013-07-31 Intercept Pharmaceuticals, Inc. Acides biliares substitues en 23 utiles comme modulateurs de tgr5 et leurs methodes d'utilisation
PT2376519E (pt) * 2008-11-19 2014-02-20 Intercept Pharmaceuticals Inc Moduladores de tgr5 e métodos da sua utilização

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PELLICCIARI, R. ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 50, 2007, pages 4265 - 4268, XP002569576 *
ROBERTO PELLICCIARI ET AL: "Discovery of 6[alpha]-Ethyl-23( S )-methylcholic Acid ( S -EMCA, INT-777) as a Potent and Selective Agonist for the TGR5 Receptor, a Novel Target for Diabesity", JOURNAL OF MEDICINAL CHEMISTRY, vol. 52, no. 24, 24 December 2009 (2009-12-24), pages 7958 - 7961, XP055099941, ISSN: 0022-2623, DOI: 10.1021/jm901390p *
SATO HIROYUKI ET AL: "Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 51, no. 6, 27 March 2008 (2008-03-27), pages 1831 - 1841, XP002520339, ISSN: 0022-2623, [retrieved on 20080229] *

Also Published As

Publication number Publication date
HK1205132A1 (en) 2015-12-11
EA201400258A1 (ru) 2015-02-27
KR101667436B1 (ko) 2016-10-18
EP2376519B1 (fr) 2013-11-13
EP2698375A2 (fr) 2014-02-19
ES2663948T3 (es) 2018-04-17
US8445472B2 (en) 2013-05-21
JP2018100304A (ja) 2018-06-28
CN104370990A (zh) 2015-02-25
WO2010059853A1 (fr) 2010-05-27
PT2698375T (pt) 2018-05-25
AU2009316566A1 (en) 2010-05-27
EA020140B1 (ru) 2014-08-29
HK1166327A1 (en) 2012-10-26
PL2376519T3 (pl) 2014-04-30
SG10201400162QA (en) 2014-05-29
PL2698375T3 (pl) 2018-08-31
NO2698375T3 (fr) 2018-07-21
AU2009316566B2 (en) 2014-04-17
JP2012509348A (ja) 2012-04-19
US8114862B2 (en) 2012-02-14
AU2009316566B9 (en) 2014-05-15
KR20160122272A (ko) 2016-10-21
US20140100209A1 (en) 2014-04-10
CA2744189C (fr) 2016-10-11
US20180016295A1 (en) 2018-01-18
IL244812A0 (en) 2016-05-31
IL264796B (en) 2020-11-30
JP2017132803A (ja) 2017-08-03
DK2376519T3 (da) 2014-02-03
CN102325784B (zh) 2014-11-19
CA2744189A1 (fr) 2010-05-27
JP2015232020A (ja) 2015-12-24
ZA201104077B (en) 2012-02-29
JP2014159456A (ja) 2014-09-04
PT2376519E (pt) 2014-02-20
BRPI0921983B8 (pt) 2021-05-25
EA201170714A1 (ru) 2012-01-30
KR20110086177A (ko) 2011-07-27
DK2698375T3 (en) 2018-05-28
HUE039171T2 (hu) 2018-12-28
US9650409B2 (en) 2017-05-16
LT2698375T (lt) 2018-07-10
SI2698375T1 (sl) 2018-10-30
IL244812B (en) 2019-03-31
MX2011005295A (es) 2011-06-24
EA030681B1 (ru) 2018-09-28
EP2698375B1 (fr) 2018-02-21
US20210269473A1 (en) 2021-09-02
ES2458168T3 (es) 2014-04-30
BRPI0921983B1 (pt) 2021-04-20
CN102325784A (zh) 2012-01-18
US20100152151A1 (en) 2010-06-17
US20120115832A1 (en) 2012-05-10
BRPI0921983A2 (pt) 2018-07-10
JP5535233B2 (ja) 2014-07-02
IL212969A (en) 2016-04-21
KR101789960B1 (ko) 2017-10-25
AU2009316566A2 (en) 2011-07-14
EP2376519A1 (fr) 2011-10-19
IL212969A0 (en) 2011-07-31

Similar Documents

Publication Publication Date Title
EP2698375A3 (fr) Modulateurs de TGR5 et leur procédé d'utilisation
WO2016205475A3 (fr) Modulateurs de tgr5 et leurs procédés d'utilisation
JP2009502793A5 (fr)
WO2010014836A3 (fr) Modulateurs de tgr5 et leurs procédés d'utilisation
EP2550965A3 (fr) Dérivés de céramide pour le traitement de la polykystose rénale
EP2368551A8 (fr) Procédés pour l'utilisation d'analogues de la cyclopamine
EP2325186A3 (fr) Inhibiteurs de mTOR bicycliques condensés
CY2016040I1 (el) Επιλογες θεραπειας για τη νοσο του fabry
EP2494932A3 (fr) Appareil pour le traitement des hémorragies intracrâniennes
ZA200808178B (en) Imidazolothiazole compounds for the treatment of disease
EP3778605A3 (fr) Inhibiteurs de lrrk2 et leurs méthodes de production et d'utilisation
EP1933883A4 (fr) Methodes et compositions pour le diagnostic de maladies renales mediees par l'iga et l'igm
SI2820009T1 (en) Serine / Threonine kinase inhibitors
EP2592070A3 (fr) Arylamides de tétrazole substitués
TW200736252A (en) Novel heteroaryl substituted benzothiazoles
PT1948615E (pt) Derivados de pirazol úteis para o tratamento de doenças ginecológicas
EP2656842A3 (fr) Modulateur de récepteur androgène pour le traitement du cancer de la prostate et de maladies associées au récepteur androgène
IL190338A0 (en) Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
EA201000886A1 (ru) Органические соединения
EP1928453A4 (fr) Procedes et compositions permettant de prevenir et de traiter les maladies renales
EP2889312A3 (fr) Traitement de maladies auto-immunes par modulation d'annexin-1 (lipocortine 1)
EP2527472A3 (fr) Une lésion génétique associée à un cancer
EP2474323A3 (fr) Dérivés d'imidazoquinoline et de pyrimidine en tant que modulateurs puissants de processus angiogènes à commande VEGF
WO2008059370A8 (fr) Composés bicyclocarboxyamides substitués
EP3091019A3 (fr) Dérivés de purine utiles comme inhibiteurs de hsp90

Legal Events

Date Code Title Description
PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AC Divisional application: reference to earlier application

Ref document number: 2376519

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA RS

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA RS

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 1/16 20060101ALI20140205BHEP

Ipc: C07J 9/00 20060101AFI20140205BHEP

Ipc: C07J 31/00 20060101ALI20140205BHEP

Ipc: C07J 41/00 20060101ALI20140205BHEP

Ipc: A61K 31/575 20060101ALI20140205BHEP

17P Request for examination filed

Effective date: 20140912

RAX Requested extension states of the european patent have changed

Extension state: RS

Payment date: 20140912

Extension state: AL

Payment date: 20140912

Extension state: BA

Payment date: 20140912

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

17Q First examination report despatched

Effective date: 20160216

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20170828

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AC Divisional application: reference to earlier application

Ref document number: 2376519

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA RS

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602009050927

Country of ref document: DE

Ref country code: AT

Ref legal event code: REF

Ref document number: 971591

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180315

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2663948

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20180417

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 2698375

Country of ref document: PT

Date of ref document: 20180525

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20180521

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20180524

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E015357

Country of ref document: EE

Effective date: 20180417

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: INTERCEPT PHARMACEUTICALS, INC.

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20180221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180521

REG Reference to a national code

Ref country code: HU

Ref legal event code: HC9C

Owner name: INTERCEPT PHARMACEUTICALS, INC., US

Free format text: FORMER OWNER(S): INTERCEPT PHARMACEUTICALS, INC., US

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20180401272

Country of ref document: GR

Effective date: 20181012

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602009050927

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E039171

Country of ref document: HU

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20181122

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 30231

Country of ref document: SK

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 971591

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180221

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MT

Payment date: 20201103

Year of fee payment: 12

Ref country code: RO

Payment date: 20201105

Year of fee payment: 12

Ref country code: LT

Payment date: 20201103

Year of fee payment: 12

Ref country code: MC

Payment date: 20201104

Year of fee payment: 12

Ref country code: CZ

Payment date: 20201105

Year of fee payment: 12

Ref country code: HU

Payment date: 20201117

Year of fee payment: 12

Ref country code: LU

Payment date: 20201127

Year of fee payment: 12

Ref country code: EE

Payment date: 20201103

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SI

Payment date: 20201103

Year of fee payment: 12

Ref country code: SK

Payment date: 20201102

Year of fee payment: 12

Ref country code: LV

Payment date: 20201106

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20211126

Year of fee payment: 13

Ref country code: NL

Payment date: 20211126

Year of fee payment: 13

Ref country code: NO

Payment date: 20211126

Year of fee payment: 13

Ref country code: IE

Payment date: 20211129

Year of fee payment: 13

Ref country code: FR

Payment date: 20211124

Year of fee payment: 13

Ref country code: ES

Payment date: 20211201

Year of fee payment: 13

Ref country code: FI

Payment date: 20211126

Year of fee payment: 13

Ref country code: DK

Payment date: 20211129

Year of fee payment: 13

Ref country code: GB

Payment date: 20211129

Year of fee payment: 13

Ref country code: AT

Payment date: 20211103

Year of fee payment: 13

Ref country code: PT

Payment date: 20211109

Year of fee payment: 13

Ref country code: SE

Payment date: 20211127

Year of fee payment: 13

Ref country code: TR

Payment date: 20211108

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20211122

Year of fee payment: 13

Ref country code: IS

Payment date: 20211102

Year of fee payment: 13

Ref country code: GR

Payment date: 20211126

Year of fee payment: 13

Ref country code: CH

Payment date: 20211202

Year of fee payment: 13

Ref country code: BE

Payment date: 20211129

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20211104

Year of fee payment: 13

REG Reference to a national code

Ref country code: LT

Ref legal event code: MM4D

Effective date: 20211119

REG Reference to a national code

Ref country code: EE

Ref legal event code: MM4A

Ref document number: E015357

Country of ref document: EE

Effective date: 20211130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211119

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211119

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211119

Ref country code: LT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211119

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211120

Ref country code: EE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211130

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211119

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211120

Ref country code: LV

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211119

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20220708

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602009050927

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20221130

REG Reference to a national code

Ref country code: NO

Ref legal event code: MMEP

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20221201

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 971591

Country of ref document: AT

Kind code of ref document: T

Effective date: 20221119

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20221119

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20221130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230519

Ref country code: NO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221130

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221130

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221130

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221119

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221120

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221201

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230609

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221119

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221119

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221119

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221130

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230601

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221130

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221130

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20240102

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221120

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221120

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221119

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221119